Ascentage Pharma Group International - American Depository Shares

Components and weights we consider: Intangible assets/patents 35 percent, Switching costs 20 percent, Network effects 5 percent, Cost advantages 20 percent, Efficient scale 20 percent. Intangible assets/patents: moderate to strong.

The company reports hundreds of issued patents globally and product‑specific patent estates with expiries stretching into the late 2030s and early 2040s, supporting durability if the assets globalize. Score 65/100. Switching costs: modest.

While hematology patients often remain on effective therapies, competitive alternatives in CML (for example, established TKIs) and the need to negotiate NRDL terms limit stickiness. Score 40/100. Network effects: none. Score 0/100. Cost advantages: limited.

Ascentage has internal manufacturing scale and an EU QP zero‑deficiency audit, but innovative oncology depends more on clinical value than unit cost, and China reimbursement constrains pricing. Score 40/100. Efficient scale: niche hematology indications can exhibit efficient scale if few competitors serve rare subpopulations.

In CML T315I and BTK‑pretreated CLL, competition exists but is limited, giving potential local efficient scale in China that could expand if global approvals arrive. Score 45/100. Weighted outcome yields a moat score near 45.